Login Register Cart 0
Generic placeholder image

Current Traditional Medicine

Editor-in-Chief

ISSN (Print): 2215-0838
ISSN (Online): 2215-0846

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Critical Study on the Synthetic and Herbal Medication Pattern in the Management of Psoriasis

Author(s): Shobhini Chandel*, Saumya Das, Neha and Vijayant Singh Chauhan

Volume 11, Issue 3, 2025

Published on: 30 October, 2023

Article ID: e241023222605 Pages: 18

DOI: 10.2174/0122150838251874231011093514

Price: $65

Abstract

Psoriasis is a chronic skin condition characterized by the rapid buildup of skin cells, leading to thick, silvery scales and red, irritated, and dry patches. It It is an autoimmune skin condition that is incurable, non-contagious, and characterized by a relapsing-remitting course. that is incurable, non-contagious, and relapsing-remitting. Typically, a remission phase lasts one to twelve months. Psoriasis is caused by a number of cellular mechanisms, and it has been hypothesised that T lymphocytes, keratinocytes, allergen cells, Langerhans cells, natural killer cells, phagocytes, a number of Th1-type chemokines, in addition to growth factors like endothelial proliferation factor and keratinocytes growth factor, among others, are key players in the development of psoriasis. Numerous synthetic medicinal drugs have been documented to have the side effects of psoriasis. Due to the safety and accessibility, herbal medications may hold promise as possible anti-psoriatic molecules. Before creating a potential herbal drug, it is important to thoroughly examine the key players in the evolution of psoriasis, such as T-cell stimulation, transportation, and cytokine inhibition. The purpose of this review is to investigate how psoriasis spreads and becomes activated, as well as how certain medications might exacerbate the condition and how certain plant resources may be used to treat psoriasis. To create a potent, secure, and dependable treatment, more scientific research on these herbal resources is required.

Keywords: Psoriasis, Cytokines, Methotrexate, Biologicals, Phototherapeutics, Herbal treatments, Capsicum frutescens.

Graphical Abstract

[1]
Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci 2020; 99(1): 2-8.
[http://dx.doi.org/10.1016/j.jdermsci.2020.05.008] [PMID: 32536600]
[2]
Gharge R, Phadatare S, Shinde S, Chogale E, Patil S, Pujare P. Psoriasis: Causes, Diagnosis and Management. Small 2021; 15: 3-4.
[3]
Pradhan M, Alexander A, Singh MR, et al. Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother 2018; 107: 447-63.
[http://dx.doi.org/10.1016/j.biopha.2018.07.156] [PMID: 30103117]
[4]
Torsekar R, Gautam M. Topical therapies in psoriasis. Indian Dermatol Online J 2017; 8(4): 235-45.
[http://dx.doi.org/10.4103/2229-5178.209622] [PMID: 28761838]
[5]
Zangeneh FZ, Shooshtary FS. Psoriasis-Types, Causes and Medication. IntechOpen 2013.
[http://dx.doi.org/10.5772/54728]
[6]
Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: Results and insights from the global burden of disease 2019 study. Front Med 2021; 8: 743180.
[http://dx.doi.org/10.3389/fmed.2021.743180] [PMID: 34977058]
[7]
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA 2020; 323(19): 1945-60.
[http://dx.doi.org/10.1001/jama.2020.4006] [PMID: 32427307]
[8]
Jawad MA, Kadhim AJ. Psoriasis-cell mediated autoimmune disease: A review. J Pharm Qual Assur 2021; 12(3): 306-10.
[9]
Benlabsir C, Riyad M, Saik IEI, et al. HLA-C genotyping reveals haplotype C*07 as a potential biomarker of late psoriasis onset in Moroccan Patients. Curr Issues Mol Biol 2023; 45(2): 1012-23.
[http://dx.doi.org/10.3390/cimb45020066] [PMID: 36826011]
[10]
Nevitt GJ, Hutchinson PE. Psoriasis in the community: Prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 1996; 135(4): 533-7.
[http://dx.doi.org/10.1046/j.1365-2133.1996.d01-1035.x] [PMID: 8915141]
[11]
Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386(9997): 983-94.
[http://dx.doi.org/10.1016/S0140-6736(14)61909-7] [PMID: 26025581]
[12]
Basavaraj KH, Navya MA, Rashmi R, Rashmi R. Stress and quality of life in psoriasis: An update. Int J Dermatol 2011; 50(7): 783-92.
[http://dx.doi.org/10.1111/j.1365-4632.2010.04844.x] [PMID: 21699511]
[13]
Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci 2019; 20(18): 4347.
[http://dx.doi.org/10.3390/ijms20184347] [PMID: 31491865]
[14]
Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol 2017; 44(8): 863-72.
[http://dx.doi.org/10.1111/1346-8138.13806] [PMID: 28349593]
[15]
Lee EB, Wu KK, Lee MP, Bhutani T, Wu JJ. Psoriasis risk factors and triggers. Cutis 2018; 102(5S): 18-20.
[PMID: 30566552]
[16]
Dogra S. DivyaKamat. Drug-induced psoriasis. Indian J Rheumatol 2019; 14: 37-43.
[17]
Gupta R, Debbaneh MG, Liao W. Genetic epidemiology of psoriasis. Curr Dermatol Rep 2014; 3(1): 61-78.
[http://dx.doi.org/10.1007/s13671-013-0066-6] [PMID: 25580373]
[18]
Jain AK, Ramesh V, Das RP. Current concepts in the pathogenesis of psoriasis. Indian J Dermatol 2009; 54(1): 7-12.
[http://dx.doi.org/10.4103/0019-5154.48977] [PMID: 20049260]
[19]
Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49(2) (Suppl.): 44-50.
[http://dx.doi.org/10.1016/S0190-9622(03)01134-4] [PMID: 12894125]
[20]
Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med 2014; 4(8): a015354.
[http://dx.doi.org/10.1101/cshperspect.a015354] [PMID: 25085957]
[21]
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20(6): 1475.
[http://dx.doi.org/10.3390/ijms20061475] [PMID: 30909615]
[22]
McGregor JM, Barker JNWN, Ross EL, MacDonald DM. Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: In situ expression of β2-integrins. J Am Acad Dermatol 1992; 27(3): 383-8.
[http://dx.doi.org/10.1016/0190-9622(92)70203-R] [PMID: 1401271]
[23]
Joshi R. Immunopathogenesis of psoriasis. Indian J Dermatol Venereol Leprol 2004; 70(1): 10-2.
[PMID: 17642549]
[24]
Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: Rationale, challenges and clinical studies. Angiogenesis 2002; 5(4): 237-56.
[http://dx.doi.org/10.1023/A:1024532022166] [PMID: 12906317]
[25]
Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis 2002; 5(4): 231-6.
[http://dx.doi.org/10.1023/A:1024515517623] [PMID: 12906316]
[26]
Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 2014; 5(1): 5621.
[http://dx.doi.org/10.1038/ncomms6621] [PMID: 25470744]
[27]
Kumar D, Rajguru JP, Maya D, Suri P, Bhardwaj S, Patel N. Update on psoriasis: A review. J Family Med Prim Care 2020; 9(1): 20-4.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_689_19] [PMID: 32110559]
[28]
Jin Y, Yang S, Zhang F, et al. Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: A hospital-based case-control study in China. J Eur Acad Dermatol Venereol 2009; 23(2): 132-7.
[http://dx.doi.org/10.1111/j.1468-3083.2008.02951.x] [PMID: 18702622]
[29]
Farkas Á, Kemény L. Alcohol, liver, systemic inflammation and skin: A focus on patients with psoriasis. Skin Pharmacol Physiol 2013; 26(3): 119-26.
[http://dx.doi.org/10.1159/000348865] [PMID: 23549156]
[30]
Højgaard P, Glintborg B, Hetland ML, et al. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis 2015; 74(12): 2130-6.
[http://dx.doi.org/10.1136/annrheumdis-2014-205389] [PMID: 25063827]
[31]
Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J. Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg 2011; 15(4): 210-9.
[http://dx.doi.org/10.2310/7750.2011.10066] [PMID: 21781627]
[32]
Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician 2017; 63(4): 278-85.
[PMID: 28404701]
[33]
Khopkar U, Nischal KC. Dermoscope. Indian J Dermatol Venereol Leprol 2005; 71(4): 300-3.
[http://dx.doi.org/10.4103/0378-6323.16633] [PMID: 16394450]
[34]
Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221(2): 176-82.
[http://dx.doi.org/10.1097/00000441-195102000-00009] [PMID: 14799481]
[35]
Carretero G, Puig L, Dehesa L, et al. Grupo de Psoriasis de la AEDV. Guidelines on the Use of Methotrexate in Psoriasis. Actas Dermosifiliogr 2010; 101(7): 600-13.
[http://dx.doi.org/10.1016/j.ad.2010.04.002]
[36]
Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol 1995; 370: 411-6.
[http://dx.doi.org/10.1007/978-1-4615-2584-4_89] [PMID: 7660940]
[37]
Elango T, Dayalan H, Gnanaraj P, Malligarjunan H, Subramanian S. Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients. Clin Exp Med 2014; 14(4): 431-7.
[http://dx.doi.org/10.1007/s10238-013-0252-7] [PMID: 23949337]
[38]
Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol 2018; 45(3): 264-72.
[http://dx.doi.org/10.1111/1346-8138.14139] [PMID: 29226422]
[39]
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012; 83(12): 1583-90.
[http://dx.doi.org/10.1016/j.bcp.2012.01.001] [PMID: 22257911]
[40]
Craven NM, Griffiths CKM. Topical retinoids and cutaneous biology. Clin Exp Dermatol 1996; 21(1): 1-10.
[http://dx.doi.org/10.1111/j.1365-2230.1996.tb00001.x] [PMID: 8689759]
[41]
Gudas LJ. Retinoids induce stem cell differentiation via epigenetic changes. Semin Cell Dev Biol 2013; 24(10-12): 701-5.
[http://dx.doi.org/10.1016/j.semcdb.2013.08.002] [PMID: 23973942]
[42]
Saurat J-H. Retinoids and psoriasis: Novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 1999; 41(3): S2-6.
[http://dx.doi.org/10.1016/S0190-9622(99)70358-0] [PMID: 10459139]
[43]
Carlberg C. Mechanisms of Nuclear Signalling by Vitamin D 3. E.J.B. Rev 1995; pp. 233-43.
[http://dx.doi.org/10.1007/978-3-642-85252-7_16]
[44]
Mattozzi C, Paolino G, Richetta AG, Calvieri S. Psoriasis, vitamin D and the importance of the cutaneous barrier’s integrity: An update. J Dermatol 2016; 43(5): 507-14.
[http://dx.doi.org/10.1111/1346-8138.13305] [PMID: 26971536]
[45]
Barrea L, Savanelli MC, Di Somma C, et al. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr Metab Disord 2017; 18(2): 195-205.
[http://dx.doi.org/10.1007/s11154-017-9411-6] [PMID: 28176237]
[46]
Trémezaygues L, Reichrath J, Vitamin D. Vitamin D analogs in the treatment of psoriasis. Dermatoendocrinol 2011; 3(3): 180-6.
[http://dx.doi.org/10.4161/derm.17534] [PMID: 22110777]
[47]
Kerkhof PCM. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol 1995; 132(5): 675-82.
[http://dx.doi.org/10.1111/j.1365-2133.1995.tb00710.x] [PMID: 7772470]
[48]
Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134(6): 1070-8.
[PMID: 8763427]
[49]
Kim HJ, Lebwohl MG. Biologics and Psoriasis. Dermatol Clin 2019; 37(1): 29-36.
[http://dx.doi.org/10.1016/j.det.2018.07.004] [PMID: 30466686]
[50]
Pithadia DJ, Reynolds KA, Lee EB, Liao W, Wu JJ. Tildrakizumab in the treatment of psoriasis: Latest evidence and place in therapy. Ther Adv Chronic Dis 2019; 10: 2040622319865658.
[http://dx.doi.org/10.1177/2040622319865658] [PMID: 31448070]
[51]
Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci 2017; 18(11): 2297.
[http://dx.doi.org/10.3390/ijms18112297] [PMID: 29104241]
[52]
Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet 2021; 397(10273): 475-86.
[http://dx.doi.org/10.1016/S0140-6736(21)00126-4] [PMID: 33549192]
[53]
Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci 2018; 33(1): 173-80.
[http://dx.doi.org/10.1007/s10103-017-2360-1] [PMID: 29067616]
[54]
Joe B, Lokesh BR. Effect of curcumin and capsaicin on arachidonic acid metabolism and lysosomal enzyme secretion by rat peritoneal macrophages. Lipids 1997; 32(11): 1173-80.
[http://dx.doi.org/10.1007/s11745-997-0151-8] [PMID: 9397403]
[55]
Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH Jr. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986; 15(3): 504-7.
[http://dx.doi.org/10.1016/S0190-9622(86)70201-6] [PMID: 3760276]
[56]
Ellis CN, Berberian B, Sulica VI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol 1993; 29(3): 438-42.
[http://dx.doi.org/10.1016/0190-9622(93)70208-B] [PMID: 7688774]
[57]
Syed TA, Ahmad SA, Holt AH, Ahmad SA, Ahmad SH, Afzal M. Management of psoriasis with Aloe vera extract in a hydrophilic cream: A placebo-controlled, double-blind study. Trop Med Int Health 1996; 1(4): 505-9.
[http://dx.doi.org/10.1046/j.1365-3156.1996.d01-91.x] [PMID: 8765459]
[58]
Klein AD, Penneys NS. Aloe vera. J Am Acad Dermatol 1988; 18(4): 714-20.
[http://dx.doi.org/10.1016/S0190-9622(88)70095-X] [PMID: 3286692]
[59]
Robson MC, Heggers JP, Hagstrom WJ Jr. Myth, magic, witchcraft, or fact? Aloe vera revisited. J Burn Care Rehabil 1982; 3(3): 154-63.
[http://dx.doi.org/10.1097/00004630-198205000-00005]
[60]
Choonhakarn C, Busaracome P, Sripanidkulchai B, Sarakarn P. A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol 2010; 24(2): 168-72.
[http://dx.doi.org/10.1111/j.1468-3083.2009.03377.x] [PMID: 19686327]
[61]
Paulsen E, Korsholm L, Brandrup F. A double-blind, placebo-controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris. J Eur Acad Dermatol Venereol 2005; 19(3): 326-31.
[http://dx.doi.org/10.1111/j.1468-3083.2004.01186.x] [PMID: 15857459]
[62]
Dhanabal SP, Priyanka Dwarampudi L, Muruganantham N, Vadivelan R. Evaluation of the antipsoriatic activity of Aloe vera leaf extract using a mouse tail model of psoriasis. Phytother Res 2012; 26(4): 617-9.
[http://dx.doi.org/10.1002/ptr.3589] [PMID: 21915932]
[63]
Sabir S, Arsshad M, Asif S, Chaudhari SK. An insight into medicinal and therapeutic potential of Silybum marianum (L.) Gaertn. Int J Biol Sci 2014; 4(11): 104-5.
[64]
Bhuchar S, Katta R, Wolf J. Complementary and alternative medicine in dermatology: An overview of selected modalities for the practicing dermatologist. Am J Clin Dermatol 2012; 13(5): 311-7.
[http://dx.doi.org/10.2165/11597560-000000000-00000] [PMID: 22668453]
[65]
Koo J, Arain S. Traditional Chinese medicine for the treatment of dermatologic disorders. Arch Dermatol 1998; 134(11): 1388-93.
[http://dx.doi.org/10.1001/archderm.134.11.1388] [PMID: 9828872]
[66]
Murti K, Panchal MA, Gajera V, Solanki J. Pharmacological properties of matricaria recutita: A review. Pharmacologia 2012; 3(8): 348-51.
[http://dx.doi.org/10.5567/pharmacologia.2012.348.351]
[67]
Safayhi H, Sabieraj J, Sailer ER, Ammon H. Chamazulene: An antioxidant-type inhibitor of leukotriene B4 formation. Planta Med 1994; 60(5): 410-3.
[http://dx.doi.org/10.1055/s-2006-959520] [PMID: 7997466]
[68]
Carson CF, Ashton L, Dry L, Smith DW, Riley TV. Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis. J Antimicrob Chemother 2001; 48(3): 450-1.
[http://dx.doi.org/10.1093/jac/48.3.450] [PMID: 11533019]
[69]
Carson CF, Riley TV, Cookson BD. Efficacy and safety of tea tree oil as a topical antimicrobial agent. J Hosp Infect 1998; 40(3): 175-8.
[http://dx.doi.org/10.1016/S0195-6701(98)90135-9] [PMID: 9830588]
[70]
Koh KJ, Pearce AL, Marshman G, Finlay-Jones JJ, Hart PH. Tea tree oil reduces histamine-induced skin inflammation. Br J Dermatol 2002; 147(6): 1212-7.
[http://dx.doi.org/10.1046/j.1365-2133.2002.05034.x] [PMID: 12452873]
[71]
May J, Chan CH, King A, Williams L, French GL. Time-kill studies of tea tree oils on clinical isolates. J Antimicrob Chemother 2000; 45(5): 639-43.
[http://dx.doi.org/10.1093/jac/45.5.639] [PMID: 10797086]
[72]
Sahu R, Jain NK, Tiwari P, Singh N, Dixit A, Singh G. Herbal Remedies: A new era for psoriasis diseases. Int J Pharm Sci Res 2011; 2(3): 525.
[73]
Brown AC, Hairfield M, Richards DG, McMillin DL, Mein EA, Nelson CD. Medical nutrition therapy as a potential complementary treatment for psoriasis-five case reports. Altern Med Rev 2004; 9(3): 297-307.
[PMID: 15387720]
[74]
Müller K, Ziereis K. The antipsoriatic Mahonia aquifolium and its active constituents; I. Pro- and antioxidant properties and inhibition of 5-lipoxygenase. Planta Med 1994; 60(5): 421-4.
[http://dx.doi.org/10.1055/s-2006-959523] [PMID: 7997469]
[75]
Mišík V, Bezáková L, Máleková Ľ, Košťálová D. Lipoxygenase inhibition and antioxidant properties of protoberberine and aporphine alkaloids isolated from Mahonia aquifolium. Planta Med 1995; 61(4): 372-3.
[http://dx.doi.org/10.1055/s-2006-958107] [PMID: 7480190]
[76]
Gulliver WP, Donsky HJ. A report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experience with Mahonia aquifolium for the treatment of plaque psoriasis. Am J Ther 2005; 12(5): 398-406.
[http://dx.doi.org/10.1097/01.mjt.0000174350.82270.da] [PMID: 16148424]
[77]
Galle K, Müller-Jakic B, Proebstle A, Jurcic K, Bladt S, Wagner H. Analytical and pharmacological studies on Mahonia aquifolium. Phytomedicine 1994; 1(1): 59-62.
[http://dx.doi.org/10.1016/S0944-7113(11)80024-3] [PMID: 23195817]
[78]
Saelee C, Thongrakard V, Tencomnao T. Effects of Thai medicinal herb extracts with anti-psoriatic activity on the expression on NF-κB signaling biomarkers in HaCaT keratinocytes. Molecules 2011; 16(5): 3908-32.
[http://dx.doi.org/10.3390/molecules16053908] [PMID: 21555979]
[79]
Shrivastav S, Sindhu R, Kumar S, Kumar P. Anti-psoriatic and phytochemical evaluation of thespesia populnea bark extracts. Int J Pharm Pharm Sci 2009; 1(1): 176-85.
[80]
Vijayalakshmi A, Ravichandiran V, Velraj M, Nirmala S, Jayakumari S. Screening of flavonoid “quercetin” from the rhizome of Smilax china Linn. for anti–psoriatic activity. Asian Pac J Trop Biomed 2012; 2(4): 269-75.
[http://dx.doi.org/10.1016/S2221-1691(12)60021-5] [PMID: 23569912]
[81]
Palaniswamy D, Nithyanantham M, Raghu PS, Dwarampudi LP. Antipsoriatic activity and cytotoxicity of ethanolic extract of Nigella sativa seeds. Pharmacogn Mag 2012; 8(32): 268-72.
[http://dx.doi.org/10.4103/0973-1296.103650] [PMID: 24082629]
[82]
Dhanabal SP, Anand R, Muruganantham N, Praveen TK, Raghu PS. Screening of Wrightia tinctoria Leaves for Anti-psoriatic Activity. Hygeia. J Med 2012; 4: 73-8.
[83]
Singh KK, Tripathy S. Natural treatment alternative for psoriasis: A review on herbal resources. J Appl Pharm Sci 2014; 4(11): 114-21.

Rights & Permissions Print Cite
Article Metrics
39
1
Wayfinder Image
© 2025 Bentham Science Publishers | Privacy Policy